{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.06","upperLimit":"0.32","value":"0.17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive ziv-aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.\n\nziv-aflibercept: Given IV","id":"OG000","title":"Treatment (Ziv-aflibercept)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"6 months","title":"Incidence of Disease Stabilization, as Measured by Progression-free Survival at 6 Months (Leiomyosaroma Group)","type":"PRIMARY","unitOfMeasure":"months"}